Vienna: Austrian biotech firm Intercell and Indian partner Biological E. Ltd. will start clinical trials with children in India for Intercell’s Japanese Encephalitis vaccine IC51.
Intercell won regulatory approval for the phase II paediatric trial, which will enrol children aged one to three starting in late April and will go on till early May, an important requirement for the introduction of the vaccine in Asia, Intercell said.
Intercell has concluded a pivotal phase III trial in Europe, Australia and the United States and expects to launch the vaccine there later this year together with Swiss drugs maker Novartis.
Over 3 billion people live in endemic areas, mainly in Asia, where mosquito-borne Japanese Encephalitis is the leading cause of childhood encephalitis and viral encephalitis.
While the vaccine is aimed at travellers in European, US and Australian markets, it will be used in a broader way in endemic regions including India.